Friday, May 29, 2015 10:09:16 AM
NASDAQ IPO: Why Now? • Core fundamentals have never been stronger and improving – In spite of achieving recent important milestones, share price has declined – Stock unable to hold gains due to short - term trading interests – Greater access to long - term institutional investors and research analysts – Therapeutics pipeline ‘institution - ready’ w/ Elto Phase 2b initiation – Pending Cutanogen acquisition will further drive institutional interest* – Begin participating in biotech bull market: IPO for AMBS onto NASDAQ • Potential of Diagnostics spinout onto NASDAQ creates leverage in negotiating with potential partners/acquirers – Relationship established with key players – Preparing to initiate formal parallel process : AMDX IPO vs. Sale • Strategic Financial Advisor for Sale • Underwriter for IPO • Better financing/negotiation options for AMBS and AMDX on NASDAQ vs. OTC 9 * = upon exercise of exclusive option to acquire Cutanogen Corporation from Lonza
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM